Resonium (Sodium Polystyrene Sulfonate) Contraindications
Resonium should be avoided in patients who cannot tolerate sodium loading (heart failure, severe hypertension, marked edema) and is contraindicated in those with obstructive bowel disease or at risk for bowel ischemia, given the serious risk of life-threatening gastrointestinal complications including colonic necrosis and perforation. 1, 2
Absolute Contraindications
Gastrointestinal Pathology
- Obstructive bowel disease or ileus - The medication can accumulate and cause mechanical obstruction 1
- History of bowel ischemia or necrosis - SPS has been directly associated with intestinal infarction, colonic necrosis, and perforation 2, 3, 4
- Post-surgical bowel anastomosis - Increased risk of perforation at surgical sites 5, 6
High-Risk Clinical Scenarios
- Uremic patients - Multiple case reports document fatal intestinal necrosis in this population 3, 4, 6
- Extremely low birth weight infants - Can cause gastric concretions and intestinal complications 7
- Hemodynamically unstable patients - Those with hypotension or compromised bowel perfusion are at markedly increased risk 5
Relative Contraindications (Use with Extreme Caution)
Sodium-Sensitive Conditions
- Heart failure - Each 15g dose contains 1500mg of sodium, which can precipitate volume overload 2
- Severe hypertension - Sodium load can worsen blood pressure control 1
- Marked edema - Additional sodium burden exacerbates fluid retention 1
Chronic Use Scenarios
- Long-term hyperkalemia management - Regulatory agencies recommend avoiding chronic use due to severe gastrointestinal side effects 1
- Patients requiring ongoing RAAS inhibitor therapy - SPS has never demonstrated a RAAS-enabling effect in controlled trials 8
Critical Safety Considerations
Black Box Warning Context
The FDA has issued warnings about severe gastrointestinal adverse effects, particularly when SPS is combined with sorbitol 1. However, complications occur even without sorbitol:
- Colonic necrosis can develop after only 3 months of low-dose therapy (30g twice weekly) 3
- Rectal stenosis from foreign body reaction to crystals 5
- Upper GI bleeding from gastric ulceration 9
- Intestinal perforation with mortality rates up to 33% 2
Mechanism of Toxicity
SPS crystals deposit in intestinal mucosa causing:
- Direct mucosal injury and inflammation 3, 6
- Ischemic changes leading to necrosis 4, 5
- Foreign body granulomatous reaction 5
- Persistent crystal retention even after discontinuation (documented up to 14 months later) 3
Preferred Alternatives
The European Heart Journal and Mayo Clinic guidelines strongly recommend newer potassium binders (patiromer or sodium zirconium cyclosilicate) over SPS due to superior safety profiles, predictable efficacy, and demonstrated RAAS-enabling effects 1, 2, 8. These agents have:
- No reported cases of intestinal necrosis 2
- Placebo-controlled trial evidence for chronic use 2
- Proven ability to maintain RAAS inhibitor therapy 8, 10
When SPS Must Be Used
If newer agents are unavailable and SPS is absolutely necessary:
- Limit to acute, short-term use only (single doses or maximum 2-3 days) 1
- Avoid sorbitol co-administration 1, 3
- Monitor closely for abdominal pain, bleeding, or change in bowel habits 3, 9
- Never use rectally in post-operative or ischemic bowel disease 4, 5
Common Pitfall to Avoid
The most dangerous error is prescribing SPS for chronic hyperkalemia management in patients on RAAS inhibitors. This approach lacks efficacy data, carries significant morbidity and mortality risk, and fails to enable optimal cardioprotective therapy 8, 10. In 2023, expert consensus states SPS "is unsafe and should not be prescribed" when safer alternatives exist 8.